TY - JOUR
T1 - The NMDA antagonist model for Schizophrenia
T2 - Promise and pitfalls
AU - Abi-Saab, W. M.
AU - D'Souza, D. C.
AU - Moghaddam, B.
AU - Krystal, J. H.
PY - 1998
Y1 - 1998
N2 - Drug models have been extensively used to study the pathophysiology of schizophrenia. While they provide good insight into the neurobiology of this disorder, they have several shortcomings, which if known, help in the interpretation of results. In this paper we will discuss these shortcomings in general, and in relation to the N-methyl D-aspartate antagonist model for schizophrenia. This model has recently received a great deal of attention since both phencyclidine and the structurally related drug ketamine, produce symptoms that extend beyond psychosis per se to include other symptoms associated with schizophrenia. In fact, subanesthetic doses of ketamine in healthy individuals produce not only paranoia and perceptual alterations but also thought disorder, negative symptoms, cognitive deficits, as well as impairment on a number of electrophysiologic tests known to be abnormal in schizophrenia. These effects of ketamine will be discussed with a particular emphasis on implications for the pathophysiology and therapeutics of this disorder.
AB - Drug models have been extensively used to study the pathophysiology of schizophrenia. While they provide good insight into the neurobiology of this disorder, they have several shortcomings, which if known, help in the interpretation of results. In this paper we will discuss these shortcomings in general, and in relation to the N-methyl D-aspartate antagonist model for schizophrenia. This model has recently received a great deal of attention since both phencyclidine and the structurally related drug ketamine, produce symptoms that extend beyond psychosis per se to include other symptoms associated with schizophrenia. In fact, subanesthetic doses of ketamine in healthy individuals produce not only paranoia and perceptual alterations but also thought disorder, negative symptoms, cognitive deficits, as well as impairment on a number of electrophysiologic tests known to be abnormal in schizophrenia. These effects of ketamine will be discussed with a particular emphasis on implications for the pathophysiology and therapeutics of this disorder.
UR - http://www.scopus.com/inward/record.url?scp=0031875396&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031875396&partnerID=8YFLogxK
U2 - 10.1055/s-2007-979354
DO - 10.1055/s-2007-979354
M3 - Review article
C2 - 9754841
AN - SCOPUS:0031875396
SN - 0176-3679
VL - 31
SP - 104
EP - 109
JO - Pharmacopsychiatry
JF - Pharmacopsychiatry
IS - SUPPL. 2
ER -